Essure — the Permanent Coils That Perforated Organs and Cost $1.6 Billion

Summary

When Bayer announced on 20 July 2018 that it would stop selling Essure in the United States by year's end, it framed the decision as a business matter — declining sales, a shrinking permanent-contraception market — and insisted, in writing, that "the benefit-risk profile of Essure has not changed" and that the device's safety and efficacy were "demonstrated by an extensive body of research." The gap between that claim and the lived record was already vast: by then the FDA had logged tens of thousands of adverse-event reports, a 2016 boxed warning sat on the label, an April 2018 order had restricted who could sell the device at all, and roughly 39,000 U.S. women would ultimately file claims describing perforated organs, coils that migrated into the abdomen, chronic pelvic pain, autoimmune reactions, and failed sterilizations. The wonder-device — sold as the only FDA-approved permanent birth control requiring no incision, no general anesthesia, and no hormones — was being withdrawn for "business reasons" precisely because the harm had made the business untenable.

Essure was a pair of nickel-titanium and stainless-steel microcoils wound with polyethylene terephthalate (PET) fibers. A clinician threaded one into each fallopian tube through the cervix; the PET fibers provoked a deliberate inflammatory response, and over roughly three months scar tissue was meant to occlude the tubes permanently. The premise was elegant and the marketing matched it: a fifteen-minute office procedure, immediate return to normal activity, "99.83% effective." The same biology that produced occlusion, however, also produced the harm. Coils perforated the thin tubal wall; fragments and whole devices migrated into the pelvis and abdomen, sometimes requiring hysterectomy to retrieve; nickel-sensitive women reacted systemically; and the occlusion was incomplete often enough to yield unintended and ectopic pregnancies.

Conceptus Inc. won FDA premarket approval (PMA P020014) in November 2002 on the strength of two non-randomized pivotal trials with no comparison arm and incomplete long-term follow-up. Bayer acquired Conceptus in 2013 for roughly $1.1 billion, inheriting both the product and a rising tide of complaints. The reckoning came not from a recall but from data the manufacturer had not generated: patient registries, a mass Facebook group ("Essure Problems") tens of thousands strong, an independent analyst's mining of the FDA's MAUDE database surfacing hundreds of reported fetal losses, and a congressman's bill to revoke the approval. The FDA imposed a boxed warning and a mandatory postmarket study in 2016, restricted sales in 2018, and watched Bayer withdraw the device worldwide by 31 December 2018 — without ever recalling the coils already inside three-quarters of a million bodies. In August 2020 Bayer agreed to pay roughly $1.6 billion to resolve about 90 percent of the U.S. claims, while still denying the device was defective.

Timeline

The No-Incision Promise and the Data That Wasn't There

Essure's appeal was its avoidance of surgery. Female sterilization had meant laparoscopic tubal ligation — an operating room, general anesthesia, incisions, recovery. Conceptus offered the same permanence as a fifteen-minute office procedure with the patient awake and walking out the same day. The pitch wrote itself, and the headline number "99.83% effective" anchored every brochure. What anchored the FDA approval was weaker than the marketing implied. The November 2002 premarket approval rested on two non-randomized pivotal studies with no comparison arm against tubal ligation, follow-up that thinned over time, and an efficacy figure conditioned on perfect coil placement and confirmed occlusion at three months. The trials were designed to demonstrate that the device could occlude tubes, not to characterize what happened to the women in whom it did not behave as designed. A permanent implant entered the bodies of hundreds of thousands of women on evidence that never asked the comparative, long-horizon questions that withdrawal would later force.

The Inflammation That Was the Point, and the Harm

The mechanism that made Essure work was the mechanism that made it dangerous. The PET fibers were chosen precisely to provoke chronic inflammation; the resulting fibrosis was the contraceptive. But fibrosis and foreign-body reaction are not surgically precise. The coils — fine, springy, anchored in a tube wall millimeters thick — perforated that wall in a measurable fraction of patients. Perforated or poorly anchored devices migrated: into the peritoneal cavity, the pelvis, occasionally the bowel, sometimes only retrievable by hysterectomy. Nickel, leaching from the nitinol, drove systemic hypersensitivity reactions in sensitized women. And the occlusion the device promised was imperfect often enough to produce thousands of reported pregnancies, including ectopic pregnancies that are life-threatening, and pregnancy losses. None of this was hidden biology; it was the predictable downside of inducing scar tissue with a metal coil. The thinness of the original trials meant the rates of these outcomes were not well characterized at approval — so the real-world denominator became the women themselves, reporting one MAUDE entry at a time.

Contributing Factors

Aftermath

Essure's material reckoning was the August 2020 agreement under which Bayer set aside roughly $1.6 billion to resolve about 90 percent of approximately 39,000 U.S. claims — without admitting the device was defective. Its durable ripple was procedural and cultural: Essure became the case study in how patient-generated data, social-media organizing, and independent database mining can force a regulatory hand that thin pivotal trials and a manufacturer's pharmacovigilance did not. The FDA's mandated 522 study, the boxed warning, and the restricted-sale order are now cited whenever a permanently implanted device reaches market on single-arm evidence. What remains is the hardware itself — coils still inside women who were never recalled, only un-sold-to — and the lingering clinical question of explantation. Today Essure is the byword for a wonder-implant withdrawn "for business reasons" by the very harm its makers refused to call a safety problem: the device whose users became its surveillance system, and then took it off the market.

Lessons

References

• Essure Permanent Birth Control U.S. Food and Drug Administration (legacy page on cacmap.fda.gov mirror; bot-blocked but resolves for humans)
• Bayer to Voluntarily Discontinue U.S. Sales of Essure at End of 2018 for Business Reasons Bayer / PR Newswire
• Essure Wikipedia
• Bayer to pay $1.6b to settle thousands of US Essure injury claims International Consortium of Investigative Journalists
• Bayer to pay $1.6 billion to settle U.S. lawsuits over Essure contraceptive device The Washington Post